Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to better understand how tenapanor affects the metagenomics and
metabolomics of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor
is the newest FDA-approved agent for IBS-C. It is a small molecule that inhibits the NHE3
receptor, leading to impaired sodium and water absorption in the intestine. Previous clinical
trials comparing tenapanor to placebo showed that a 50 mg dose of tenapanor led to increased
bowel movements and decreased abdominal pain. This study consists of an 8-week treatment
period in which subjects will ingest one capsule of tenapanor (50 mg per dose), twice daily,
and send in stool samples following 4 weeks and 8 weeks of treatment.